# Understanding the BLOCKING Act of 2021

This bill is about making generic medications more affordable and available to patients by changing how the government handles approval of competing generic drugs. Right now, when a pharmaceutical company is the first to develop a generic version of a brand-name drug, they get a special reward: a 180-day period where no other company can sell a competing generic version. This exclusivity period is meant to encourage companies to invest in creating generics. However, the bill addresses a problem where a first company can claim this 180-day protection even if they haven't actually finished getting their drug approved yet—essentially blocking competitors from entering the market while doing nothing to bring their own product to patients.

The BLOCKING Act changes this by allowing a second generic company to get approval and start selling their drug if certain conditions are met. Specifically, if at least 30 months have passed since the first company submitted their application but still hasn't received final approval, and if there's no legal reason preventing the first company from being approved, then a competing generic can move forward. The first company still gets their 180-day exclusivity period, but only if they actually get their drug approved and on the market. If they don't, they lose the ability to block competitors.

For everyday people, this means potentially lower drug prices and faster access to generic medications. When multiple generic versions compete in the market, prices typically drop because companies compete on cost. This bill prevents a situation where a company could tie up the market by claiming an exclusive period without actually delivering a product to patients. It's designed to balance two goals: still rewarding companies that successfully develop generics, while preventing unnecessary delays that keep prices high and limit patient access to affordable medications.

BLOCKING Act of 2021

Schrader, Kurt

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021 or the BLOCKING Act of 2021 This bill modifies provisions related to market exclusivity for a generic drug. Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug. The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.